JP6953400B2 - システイン反応性プローブとその使用 - Google Patents

システイン反応性プローブとその使用 Download PDF

Info

Publication number
JP6953400B2
JP6953400B2 JP2018516113A JP2018516113A JP6953400B2 JP 6953400 B2 JP6953400 B2 JP 6953400B2 JP 2018516113 A JP2018516113 A JP 2018516113A JP 2018516113 A JP2018516113 A JP 2018516113A JP 6953400 B2 JP6953400 B2 JP 6953400B2
Authority
JP
Japan
Prior art keywords
cysteine
protein
small molecule
containing protein
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018516113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501363A5 (enExample
JP2019501363A (ja
Inventor
エフ． クラバット，ベンジャミン
エフ． クラバット，ベンジャミン
エム． バッカス，ケリアン
エム． バッカス，ケリアン
イー． コレイア，ブルーノ
イー． コレイア，ブルーノ
エム． ブルーエット，メーガン
エム． ブルーエット，メーガン
アール． テイジャロ，ジョン
アール． テイジャロ，ジョン
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019501363A publication Critical patent/JP2019501363A/ja
Publication of JP2019501363A5 publication Critical patent/JP2019501363A5/ja
Application granted granted Critical
Publication of JP6953400B2 publication Critical patent/JP6953400B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01023—Protein-arginine N-methyltransferase (2.1.1.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22061—Caspase-8 (3.4.22.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22063—Caspase-10 (3.4.22.63)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018516113A 2015-10-22 2016-10-21 システイン反応性プローブとその使用 Expired - Fee Related JP6953400B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562244881P 2015-10-22 2015-10-22
US62/244,881 2015-10-22
US201662345710P 2016-06-03 2016-06-03
US62/345,710 2016-06-03
PCT/US2016/058308 WO2017070611A1 (en) 2015-10-22 2016-10-21 Cysteine reactive probes and uses thereof

Publications (3)

Publication Number Publication Date
JP2019501363A JP2019501363A (ja) 2019-01-17
JP2019501363A5 JP2019501363A5 (enExample) 2020-01-30
JP6953400B2 true JP6953400B2 (ja) 2021-10-27

Family

ID=58558160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516113A Expired - Fee Related JP6953400B2 (ja) 2015-10-22 2016-10-21 システイン反応性プローブとその使用

Country Status (5)

Country Link
US (2) US10670605B2 (enExample)
EP (1) EP3365686A4 (enExample)
JP (1) JP6953400B2 (enExample)
CA (1) CA3001847A1 (enExample)
WO (1) WO2017070611A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
US10670605B2 (en) 2015-10-22 2020-06-02 The Scripps Research Institute Cysteine reactive probes and uses thereof
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
US20190216893A1 (en) * 2016-06-03 2019-07-18 The Scripps Research Institute Compositions and methods of modulating immune response
CA3050260A1 (en) 2017-01-18 2018-07-26 The Scripps Research Institute Photoreactive ligands and uses thereof
WO2018144869A1 (en) * 2017-02-03 2018-08-09 The Regents Of The University Of California Compositons and methods for modulating uba5
SG11201906671SA (en) * 2017-02-03 2019-08-27 Univ California Compositions and methods for inhibiting reticulon 4
US20200054651A1 (en) * 2017-02-03 2020-02-20 The Regents Of The University Of California Compositions and methods for modulating ppp2r1a
EP3688472A4 (en) * 2017-09-27 2021-06-23 The Scripps Research Institute CONJUGATED PROTEINS AND THEIR USES
WO2019067733A1 (en) * 2017-09-27 2019-04-04 Vividion Therapeutics, Inc. COMPOUNDS AND METHODS FOR MODULATING PROTEIN DEGRADATION
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019113724A1 (zh) * 2017-12-11 2019-06-20 广州君赫生物科技有限公司 双硫仑的新应用
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US12366579B2 (en) 2019-03-21 2025-07-22 University Of Virginia Patent Foundation Sulfur-heterocycle exchange chemistry and uses thereof
EP4010459A4 (en) 2019-08-05 2023-09-06 Bridgene Biosciences, Inc. Method for proteome-wide discovery of covalent ligands and compositions thereof
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
CN114787632A (zh) * 2019-10-15 2022-07-22 杰那医疗公司 反应性亲和探针相互作用发现平台
US20240123078A1 (en) * 2019-10-16 2024-04-18 Vividion Therapeutics, Inc. Compounds and methods for modulating immune-related proteins
EP4045050A4 (en) * 2019-10-16 2023-11-08 The Scripps Research Institute An activity-guided map of electrophile-cysteine interactions in primary human immune cells
CN111063389B (zh) * 2019-12-04 2021-10-29 浙江工业大学 一种基于深度卷积神经网络的配体绑定残基预测方法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN112255396A (zh) * 2020-10-15 2021-01-22 南开大学 一种测量小分子药物抑制蛋白核酸互作的单分子力学方法
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CN117956996A (zh) * 2021-05-11 2024-04-30 Opna 生物公司 用于yap/tead调节的化合物和方法及其适应证
US20250034216A1 (en) * 2021-11-22 2025-01-30 The Scripps Research Institute Stereoselective covalent ligands for oncogenic and immunological proteins
US20260079154A1 (en) * 2022-09-12 2026-03-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Composition, device, system, and methods for detecting environmental toxicants
WO2024073486A2 (en) * 2022-09-28 2024-04-04 The General Hospital Corporation Probes and methods to identify ligandable fatty acylation sites for therapeutic target identification
CN116466423B (zh) * 2023-04-26 2026-05-01 中国科学院化学研究所 一种手性选择的光滤波器及其应用
CN116790698B (zh) * 2023-06-21 2024-06-18 南京大学 基于氧化脱羧酶的硫醛合成方法及其应用
WO2025182683A1 (ja) * 2024-02-29 2025-09-04 国立大学法人 東京大学 タンパク質の活性／反応性部位の、活性／反応性の評価方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
WO2000077184A1 (en) * 1999-06-10 2000-12-21 Pharmacia & Upjohn Company Caspase-8 crystals, models and methods
AU2573102A (en) * 2000-11-21 2002-06-03 Sunesis Pharmaceuticals Inc An extended tethering approach for rapid identification of ligands
WO2005118833A2 (en) 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
US7935479B2 (en) 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
WO2008094205A2 (en) * 2006-08-04 2008-08-07 The Board Of Trustees Of The Leland Stanford Junior University A mild chemically cleavable linker system
JPWO2008029924A1 (ja) * 2006-09-08 2010-01-21 大日本住友製薬株式会社 環状アミノアルキルカルボキサミド誘導体
US20090068107A1 (en) 2006-10-02 2009-03-12 The Scripps Research Institute Enzyme regulating ether lipid signaling pathways
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
WO2008109997A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Procaspase 8-mediated disease targeting
EP2254574A1 (en) * 2008-02-26 2010-12-01 Ludwig-Maximilians-Universität München Beta-lactones as antibacterial agents
WO2013192364A1 (en) * 2012-06-22 2013-12-27 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
US20140357512A1 (en) 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
WO2016029037A1 (en) 2014-08-21 2016-02-25 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
US10670605B2 (en) * 2015-10-22 2020-06-02 The Scripps Research Institute Cysteine reactive probes and uses thereof
CA3050260A1 (en) 2017-01-18 2018-07-26 The Scripps Research Institute Photoreactive ligands and uses thereof

Also Published As

Publication number Publication date
US20170115303A1 (en) 2017-04-27
US20200292555A1 (en) 2020-09-17
CA3001847A1 (en) 2017-04-27
EP3365686A1 (en) 2018-08-29
US10670605B2 (en) 2020-06-02
EP3365686A4 (en) 2019-03-27
JP2019501363A (ja) 2019-01-17
WO2017070611A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
US20200292555A1 (en) Cysteine reactive probes and uses thereof
US12366579B2 (en) Sulfur-heterocycle exchange chemistry and uses thereof
Fan et al. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
Wisén et al. Binding of a small molecule at a protein–protein interface regulates the chaperone activity of hsp70–hsp40
US10859585B2 (en) Lipid probes and uses thereof
CA3195950A1 (en) Compounds for targeted protein degradation of kinases
AU2018211066B2 (en) Photoreactive ligands and uses thereof
Pei et al. Exploring protein S-palmitoylation: mechanisms, detection, and strategies for inhibitor discovery
US20210255193A1 (en) Lysine reactive probes and uses thereof
US20240400542A1 (en) Sulfonyl-triazoles useful as covalent kinase ligands
US20200278355A1 (en) Conjugated proteins and uses thereof
Harding et al. Discovery and characterization of a chemical probe targeting the zinc-finger ubiquitin-binding domain of HDAC6
Kumar et al. Chemically targeting the redox switch in AP1 transcription factor ΔFOSB
Lv et al. Cyclopropenone, cyclopropeniminium ion, and cyclopropenethione as novel electrophilic warheads for potential target discovery of triple-negative breast cancer
Withers-Martinez et al. Peptidic boronic acid Plasmodium falciparum SUB1 inhibitors with improved selectivity over human proteasome
Singh et al. Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma
US20240123078A1 (en) Compounds and methods for modulating immune-related proteins
Porta et al. Activity-based chemoproteomic profiling reveals the active kinome of Leishmania
King Utilizing Proteolysis-Targeting Chimeras to Target the Transcriptional Cyclin-Dependent Kinases 9 and 12
Kabir Investigation of E3 Ligase Ligands for Targeted Protein Degradation
Syphers et al. Meeting Proceedings from ICBS 2022–Uncovering Solutions for Diseases
Allan Novel Ligands for the Treatment of Rare Diseases: A Focus on Fibrolamellar Hepatocellular Carcinoma (FLC) and Duchenne Muscular Dystrophy (DMD)
Ward Tool development to study ubiquitination machinery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210929

R150 Certificate of patent or registration of utility model

Ref document number: 6953400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees